Géraldine Perkins

Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study

Emily Alouani, Julien Taı̈eb, David Tougeron, Guillaume Roces et autres

BACKGROUND: Tumors with mismatch repair deficiency (MMRd) classically display concomitant loss of MLH1/PMS2 or MSH2/MSH6 on immunohistochemistry (IHC) with microsatellite instability-high (MSI-High) status on molecular testing. Nevertheless, a different phenotype can occur in up to 15% of MMRd tumors (unusual phenotype). Data …

fr, us, be (code pays fourni par la source)

Potential barriers to performing adapted physical activity in patients with digestive cancer: results of the prospective observational APACADIG study

Clémence Trihan, Cindy Richard, Émeric Boisteau, Thomas Grainville et autres

Background: Adapted physical activity (APA) is key supportive care in cancer patients. Very few studies have evaluated APA in digestive cancers, and the eligibility and feasibility of an APA program in this population have not been clearly defined. Objectives: Primary objective: to …

fr (code pays fourni par la source)

Thrombopénie immunologique induite par chimiothérapie : un coupable peut en cacher un autre

F. Therme, Juliette Guiraud-Chaumeil, Géraldine Perkins, Margaux Lafaurie et autres

INTRODUCTION: Drug-induced immune thrombocytopenia (DIIT) is a rare cause of immune thrombocytopenia, characterized by the formation of drug-dependent antiplatelet antibodies. DIIT can lead to life-threatening hemorrhage. The diagnosis is difficult, relying on the detection of antiplatelet antibodies in patient's serum exclusively in …

fr, Maroc (code pays fourni par la source)

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

Francesca Aroldi, Elena Élez, Thierry André, Géraldine Perkins et autres

BACKGROUND: Targeting RAS mutant (MT) colorectal cancer (CRC) remains a difficult challenge, mainly due to the pervasiveness of RAS/MEK-mediated feedback loops. Preclinical studies identified MET/STAT3 as an important mediator of resistance to KRAS-MEK1/2 blockade in RASMT CRC. This dose escalation/expansion study assessed …

gb, es, fr, be, cz, it, ie (code pays fourni par la source)

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Peter F. Gallagher, Christian Rolfo, Elena Élez, Julien Taı̈eb et autres

BACKGROUND: Single-agent MEK1/2 inhibition has been disappointing in clinical trials targeting RAS mutant (MT) cancers, probably due to upstream receptor activation, resulting in resistance. We previously found that dual c-MET/MEK1/2 inhibition attenuated RASMT colorectal cancer (CRC) xenograft growth. In this study, we …

gb, be, es, fr, it, cz, ie (code pays fourni par la source)

Encorafenib, binimetinib and cetuximab in BRAF V600E-mutated advanced pancreatic adenocarcinoma

Aziz Zaanan, Victoire Dabout, Simon Garinet, D Giraud et autres

fr (code pays fourni par la source)

Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study

C. Gallois, Elisabeth Bergen, Édouard Auclin, Simon Pernot et autres

BACKGROUND: The combination of encorafenib with cetuximab has become the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC) after a prior systemic therapy. This study aims to describe the efficacy and safety of encorafenib/cetuximab +/- binimetinib in patients …

fr, at, it, be, us, de, es (code pays fourni par la source)

BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

Margherita Ambrosini, David Tougeron, Dominik Paul Modest, Rosine Guimbaud et autres

fr, it, de, us, es (code pays fourni par la source)

Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)

Vincent Hautefeuille, Nicolas Williet, Anthony Turpin, Bertrand Napoléon et autres

BACKGROUND: Management of ampullary tumors (AT) is challenging because of a low level of scientific evidence. This document is a summary of the French intergroup guidelines regarding the management of AT, either adenoma (AA) or carcinoma (AC), published in July 2023, available …

fr (code pays fourni par la source)

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

Mathilde Moreau, Emily Alouani, Clémence Flecchia, Antoine Falcoz et autres

BACKGROUND: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced …

fr, be, us (code pays fourni par la source)

Braf + Egfr +/- Mek Inhibitors after Immune Checkpoint Inhibitors In Braf V600e Mutated and Deficient Mismatch Repair or Microsatellite Instability High Metastatic Colorectal Cancer

Margherita Ambrosini, David Tougeron, Dominik Paul Modest, Rosine Guimbaud et autres

it, fr, de, us, cz, es (code pays fourni par la source)

Les formes héréditaires et familiales des adénocarcinomes pancréatiques : déterminisme génétique, population éligible à un dépistage systématique, modalités et résultats du dépistage

Ugo Marchèse, Vinciane Rebours, Alain Sauvanet, Olivier Caron et autres

fr (code pays fourni par la source)